Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Relax Endpoint Requirements For Emergency Research, Novo Nordisk Says

This article was originally published in The Pink Sheet Daily

Executive Summary

“Reduction of substantial morbidity alone should be sufficient” benefit in medical trials conducted under emergency conditions, the firm says.

You may also be interested in...



NovoSeven Wins Expanded Indication For Acquired Hemophilia

Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.

NovoSeven Wins Expanded Indication For Acquired Hemophilia

Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.

Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study

Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel